Qiagen reported soft Q2 results, as a severe decline in COVID-19 sales overshadowed the high-single-digit growth for the non-COVID-19 product group. More importantly, the guidance was downgraded which also incorporates the unpredictability in bulk orders in the OEM business. Overall, considering the resilient demand for routine testing, along with continuous innovation and balance sheet strength, we reiterate our positive recommendation.